Cite

HARVARD Citation

    Marron, T. et al. (2022). Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet gastroenterology and hepatology. pp. 219-229. [Online]. 
  
Back to record